BioNTech signs agreement to acquire Biotheus
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
NBC Washington20d
Fact Check: Q&A on the 2024-2025 COVID-19 Vaccines
On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer/BioNTech and Moderna, for ages 6 months and up. About a week later ...
Mining21d
Arkansas lithium projects heat up with royalty battle, huge underground resource
The Arkansas Oil and Gas Commission on Nov. 4 is to hear an application filed by those companies and others to potentially set the royalty rate. They have proposed a 1.82% royalty, while ...
News2422d
TIMELINE | Rachel and Siya Kolisi's emotional journey: The highs and lows of SA's rugby royalty
In a heart-wrenching turn of events, Springbok star Siya Kolisi and his wife Rachel have announced their separation. The couple shared a joint statement on Instagram on Tuesday evening. "We wanted to ...
Yahoo Finance23d
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
EMERYVILLE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) announced today it has entered into a $15 million royalty monetization arrangement with Twist ...
FactCheck.org23d
Q&A on the 2024-2025 COVID-19 Vaccines
On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer/BioNTech and Moderna, for ages 6 months and up. About a week later ...
Morningstar24d
BioNTech's mRNA Technology and Acquired Oncology Programs Could Support a Future Moat
assuming a roughly 15% royalty/gross profit share and more than EUR 500 million in annual revenue to BioNTech by 2033. Overall, the company’s clinical pipeline contributes about EUR 7 billion in ...
Pharmaceutical Technology24d
FDA clamps partial hold on Phase III trial of BioNTech & OncoC4’s NSCLC therapy
Image credit: Andrii Yalanskyi / Shutterstock. The US Food and Drug Administration (FDA) has placed a partial clinical hold on the registrational Phase III PRESERVE-003 trial of BioNTech and OncoC4’s ...
Seeking Alpha27d
BioNTech and Moderna: A tale of two mRNA developers
In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...
NDTV27d
5 Luxury Tea Brands In India That Will Make You Feel Like Royalty
Tea culture in India is steeped in tradition, craftsmanship and warmth. India's finest teas are the product of a centuries-old tradition. These luxury teas are nothing short of extraordinary. In India ...
FierceBiotech27d
BioNTech-OncoC4 phase 3 cancer trial under partial hold after varying results reported
The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing varying results among patients. The hold impacts an open-label trial ...
HELLO! Magazine28d
Prince Harry surprises with adventurous outing without Meghan Markle following return from Africa
Welcome to The HELLO! Royal Club, where thousands of royal fans like you get to delve deeper into the wonderful world of royalty every day. Want to join them? Just click the button below for a ...